Actually a good chart position / funadmentals
iBorrowdesk.com the short fee just doubled from 17 to 35 past 15 minutes.
News 15 min ago :
businesswire.com/news/home/20210405005386/en/Published-Peer-Reviewed-Data-Demonstrate-Bamlanivimab’s-High-Potency-Against-SARS-CoV-2-and-Support-its-Use-as-a-Foundational-Antibody-Therapy-to-Treat-and-Prevent-COVID-19/
- Study was the first of its kind to show a neutralizing antibody can decrease SARS-CoV-2 viral shedding and transmission by blocking virus replication in the upper airway
- Bamlanivimab moved from first screen to clinical testing in 90 days1 and is the world's first monoclonal antibody specifically developed against SARS-CoV-2 to receive FDA Emergency Use Authorization (EUA)2
iBorrowdesk.com the short fee just doubled from 17 to 35 past 15 minutes.
News 15 min ago :
businesswire.com/news/home/20210405005386/en/Published-Peer-Reviewed-Data-Demonstrate-Bamlanivimab’s-High-Potency-Against-SARS-CoV-2-and-Support-its-Use-as-a-Foundational-Antibody-Therapy-to-Treat-and-Prevent-COVID-19/
- Study was the first of its kind to show a neutralizing antibody can decrease SARS-CoV-2 viral shedding and transmission by blocking virus replication in the upper airway
- Bamlanivimab moved from first screen to clinical testing in 90 days1 and is the world's first monoclonal antibody specifically developed against SARS-CoV-2 to receive FDA Emergency Use Authorization (EUA)2
交易進行
Traded this at 27.20手動結束交易
Sold at 31.10
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。